| Browse All

MacroGenics, Inc. (MGNX)

Healthcare | Biotechnology | Rockville, United States | NasdaqGS
3.46 USD +0.05 (1.466%) ⇧ (April 17, 2026, 4 p.m. EDT)
After hours: 3.46

Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 11, 2026, 1:33 p.m. EDT

MGNX is a volatile biotech stock with a weak financial position, characterized by negative earnings, high debt-to-equity ratio, and a lack of consistent dividends. The recent price history shows a range-bound movement with no clear trend. While there are some signs of potential short-term momentum, the overall fundamentals and risk profile make it a speculative play. Long-term investors should be cautious, and short-term traders may look for opportunities in the dips or consider options strategies to manage risk.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.257318
AutoARIMA0.311888
AutoETS0.313135
MSTL0.316482

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 42%
H-stat 26.00
Ljung-Box p 0.000
Jarque-Bera p 0.058
Excess Kurtosis -1.74
Attribute Value
Sector Healthcare
Debt to Equity Ratio 66.129
Revenue per Share 2.367
Market Cap 219,917,840
Forward P/E -2.59
Beta 1.10
Profit Margins -49.91%
Website https://www.macrogenics.com

As of April 11, 2026, 1:33 p.m. EDT: Options speculators are showing mixed signals. The calls and puts data indicate that there is a significant amount of open interest and volume around strikes below the current price, particularly at the 2.0 strike, suggesting potential bearish sentiment. However, there is also some positioning around strikes above the current price, which could indicate bullish speculation. The overall volatility and the positioning suggest a cautious approach with limited directional clarity.


Info Dump

Attribute Value
52 Week Change 1.4532373
Address1 9,704 Medical Center Drive
All Time High 41.0
All Time Low 0.99
Ask 4.41
Ask Size 2
Average Analyst Rating 2.3 - Buy
Average Daily Volume10 Day 989,660
Average Daily Volume3 Month 1,100,716
Average Volume 1,100,716
Average Volume10Days 989,660
Beta 1.096
Bid 2.53
Bid Size 2
Book Value 0.878
City Rockville
Country United States
Crypto Tradeable 0
Currency USD
Current Price 3.46
Current Ratio 5.101
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 3.545
Day Low 3.425
Debt To Equity 66.129
Display Name MacroGenics
Earnings Call Timestamp End 1,742,502,600
Earnings Call Timestamp Start 1,742,502,600
Earnings Timestamp 1,773,086,400
Earnings Timestamp End 1,778,184,000
Earnings Timestamp Start 1,778,184,000
Ebitda -65,669,000
Ebitda Margins -0.43925998
Enterprise To Ebitda -1.016
Enterprise To Revenue 0.447
Enterprise Value 66,752,196
Eps Current Year -1.725
Eps Forward -1.335
Eps Trailing Twelve Months -1.19
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fax 301 251 5321
Fifty Day Average 2.5602
Fifty Day Average Change 0.89980006
Fifty Day Average Change Percent 0.35145694
Fifty Two Week Change Percent 145.32373
Fifty Two Week High 3.88
Fifty Two Week High Change -0.42000008
Fifty Two Week High Change Percent -0.10824744
Fifty Two Week Low 1.185
Fifty Two Week Low Change 2.275
Fifty Two Week Low Change Percent 1.9198314
Fifty Two Week Range 1.185 - 3.88
Financial Currency USD
First Trade Date Milliseconds 1,381,411,800,000
Float Shares 55,592,291
Forward Eps -1.335
Forward P E -2.5917602
Free Cashflow -58,232,124
Full Exchange Name NasdaqGS
Full Time Employees 293
Gmt Off Set Milliseconds -14,400,000
Gross Margins -0.22529
Gross Profits -33,681,000
Has Pre Post Market Data 1
Held Percent Insiders 0.03373
Held Percent Institutions 0.64571
Implied Shares Outstanding 63,560,068
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Long Name MacroGenics, Inc.
Market us_market
Market Cap 219,917,840
Market State CLOSED
Max Age 86,400
Message Board Id finmb_600911
Most Recent Quarter 1,767,139,200
Net Income To Common -74,620,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 219,282,234
Number Of Analyst Opinions 5
Open 3.48
Operating Cashflow -81,040,000
Operating Margins -0.29342
Payout Ratio 0.0
Phone 301 251 5172
Post Market Change 0.0
Post Market Change Percent 0.0
Post Market Price 3.46
Post Market Time 1,776,456,605
Previous Close 3.41
Price Eps Current Year -2.0057971
Price Hint 4
Price To Book 3.9407744
Price To Sales Trailing12 Months 1.4710224
Profit Margins -0.49912998
Quick Ratio 4.715
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key buy
Recommendation Mean 2.28571
Region US
Regular Market Change 0.05
Regular Market Change Percent 1.46627
Regular Market Day High 3.545
Regular Market Day Low 3.425
Regular Market Day Range 3.425 - 3.545
Regular Market Open 3.48
Regular Market Previous Close 3.41
Regular Market Price 3.46
Regular Market Time 1,776,456,001
Regular Market Volume 533,216
Return On Assets -0.17559999
Return On Equity -0.86945
Revenue Growth 1.13
Revenue Per Share 2.367
Sand P52 Week Change 0.36506534
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 63,560,068
Shares Percent Shares Out 0.059499998
Shares Short 3,778,755
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 4,086,628
Short Name MacroGenics, Inc.
Short Percent Of Float 0.0616
Short Ratio 2.36
Source Interval 15
State MD
Symbol MGNX
Target High Price 9.0
Target Low Price 2.0
Target Mean Price 4.8
Target Median Price 4.0
Total Cash 189,912,992
Total Cash Per Share 2.988
Total Debt 36,762,000
Total Revenue 149,500,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -1.19
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 1.855975
Two Hundred Day Average Change 1.604025
Two Hundred Day Average Change Percent 0.8642492
Type Disp Equity
Volume 533,216
Website https://www.macrogenics.com
Zip 20,850